Credit: Original article published here.Allergy season (unfortunately) is in full swing. Tree pollen typically pops up in early to late March and climate change may lead to earlier and longer pollen seasons. To cope with seasonal allergies – which are associated with itchy eyes, running noses, and even asthma flare ups – ENT specialist Dr. Aaron Westreich, of ENT and Allergy Associates in New York City, provides useful tips for managing and treating annoying, and even burdensome pollen allergies.

Credit: Original article published here.Galit Zuckerman-Stark, Founder and CEO of Medasense Biometrics, spoke with DocWire about the company’s Nociception Level Index (NOL) technology, a measure of peri-operative pain, and its potential to improve surgery outcomes. NOL technology is currently being used in several countries across the globe, and the US Food and Drug Administration recently granted marketing authorization for the NOL monitoring platform through the de novo premarket approval pathway. View More Interviews With a Variety of Specialists

Credit: Original article published here.In part two of an informative discussion, DocWire News partner Dr. Hady Lichaa continues his discussion with Dr. Matthew Bunte, a world-renowned expert on vascular and cardiac interventions. The topic at hand is deep venous arterialization (DVA), which is a technique that provides a limb-saving option for patients with chronic limb-threatening ischemia. In part one, Dr. Bunte broke down the technical nuances of the procedure. Here, Dr. Bunte details the clinical aspects of DVA procedures, recommendations he gives his patients post-DVA, what percentage of limbs are saved due to DVA, and much more. Dr. Hady Lichaa: So now, getting out of the technical aspect to the kind of program development aspect, tell us how you started. Who are the players in your program? And how do you collaborate? And how do you…? Let’s start with that. Dr. Matthew Bunte: Yeah. As a cardiologist, I have really come to appreciate how important it is to thinking about these patients almost like a transplant patient. I’m thinking about my heart failure colleagues and how there are many different clinical aspects to the case that lead you to offering these really complex solutions. But also, there’s that psychosocial dynamic,

Credit: Original article published here.Dr. Hady Lichaa:  Hello, everyone. This is Hady Lichaa, Interventional Cardiovascular Specialist from DocWire News, and I have the pleasure of having Dr. Matthew Bunte with me today. He is a world expert on vascular interventions and cardiac interventions. Extremely accomplished, had the opportunity to start building a deep venous arterialization program within their limb salvage program, and we’re kind of wanting to discuss this with him today. How are you, Dr. Bunte? Dr. Matthew Bunte: I’m great, Hady. Thanks so much for having me today, and looking forward to the discussion. Dr. Hady Lichaa: Yes, sir. So, if you can let the audience know about what you do mostly, especially on the endovascular side, and then we can delve into the topic. Dr. Matthew Bunte: Yeah. Well, hello, everybody. I’m Matt Bunte. I’m from the Saint Luke’s Mid America Heart Institute in Kansas City, Missouri. I also am an associate professor at the University of Missouri Kansas City School of Medicine, and I’m the Director of Vascular Medicine for our health system. And my endovascular practice includes both artery and venous interventions, but more heavily focused on peripheral artery disease and chronic limb-threatening ischemia, which

Credit: Original article published here.The Oncology Brothers are joined by Dr. Margaret Gatti-Mays, of the Ohio State Comprehensive Cancer Center, to cover the current standard of treatment care in hormone receptor positive breast cancer. In this episode, Dr. Gatti-Mays walks through approach for treating women with this type of cancer using a treatment algorithm based on both disease stage (early stage, locally advanced, advanced/metastatic), and patient age (premenopausal vs. postmenopausal). Dr. Gatti-Mays expressed her excitement for being a breast oncologist based on “the amazing advancements that have occurred within the last couple of years.”

Credit: Original article published here.In this episode of The Fellow on Call: The Heme/Onc Podcast:Radiation oncology resident Dr. Ryan Miller, of Thomas Jefferson University Hospital, joins the group for the second time to discuss the critical role of radiation therapy in breast cancer management. Specifically, the group details the guidance breast cancer patients receive prior to undergoing radiation therapy, the standard radiation dosing administered to patients following breast cancer surgery, the common side effects of radiation therapy, and much more.

Credit: Original article published here.Researchers at Karolinska Institutet in Sweden have recently made a significant discovery that could pave the way for a simple and non-invasive screening procedure for Alzheimer’s disease (AD). The study, which was published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, shows that a type of sugar molecule known as bisecting N-acetylglucosamine glycan epitope is linked to tau protein, which is a key factor in the progression of advanced dementia and AD. The research team has previously established a correlation between the levels of glycan and tau protein in individuals with AD. However, these analyses were done on cerebrospinal fluid which is difficult to obtain and can be considered invasive. “The role of glycans, structures made up of sugar molecules, is a relatively unexplored field in dementia research,” Robin Zhou, medical student at Karolinska Institutet and lead author of the study, stated.  Glycans are sugar molecules located on the surface of proteins that dictate the function and placement of these proteins in the body. By measuring blood glycan levels, the researchers found that individuals with matching levels of glycans and tau were over twice as likely to develop Alzheimer’s-type dementia. The team of researchers

Credit: Original article published here.In this episode of Healthcare Unfiltered:Mike Rucker, PhD, a behavioral scientist and organizational psychologist, joins Dr. Chadi Nabhan show to discuss his writing and publishing of the book “The Fun Habit: How the Pursuit of Joy and Wonder Can Change Your Life.” Dr. Rucker explains how you can build having fun into an “actionable and effortless habit” and simultaneously reduce burnout. He shares why Americans have a difficult time enjoying themselves outside of work, what it means to “stop chasing happiness and start having fun,” and much more.

Credit: Original article published here.There is increasing recognition that left ventricle (LV) unloading is important for patients in cardiogenic shock supported by venous-arterial extracorporeal membrane oxygenation (VA-ECMO) – particularly, those in shock due to acute myocardial infarction (CS-AMI).1 Unloading the LV is commonly performed by inserting additional temporary mechanical circulatory support (tMCS), including devices like a percutaneous left ventricular assist device (pVAD, i.e., Impella®), CentriMag®, or an intra-aortic balloon pump.2 One approach to unload the LV during VA-ECMO that is infrequently used involves placement of a left-atrial drainage catheter that is placed via interatrial transseptal puncture. This would allow for direct left atrial drainage, thereby reducing pulmonary capillary wedge pressure and left ventricular preload thereby unloading the LV. This strategy is described as left atrial VA-ECMO or “LAVA-ECMO”. During the 2023 Houston Shock Symposium, Dr. William W. O’Neill presented a case report about a patient with severe aortic regurgitation resulting in cardiogenic shock requiring the use of LAVA-ECMO as a bridge to definitive repair. Dr. Jeffrey Wang had a poster presentation on a case report on a patient with refractory cardiogenic shock initially cannulated with VA-ECMO as a bridge to heart transplant. However, the patient developed worsening pulmonary edema requiring

Credit: Original article published here.Virax Biolabs, is a company developing a game-changing immunology platform based around T-Cell testing called Virax Immune. The recent pandemic and ongoing ‘tripledemic’ have made the public more aware of viral threats while raising curiosity of one’s own susceptibility to these threats. Virax Immune is a proprietary T cell testing platform to determine whether an individual will be able to mount a robust response to an infection. T cell tests are more informative than antibody and antigen testing as T cells provide long-term immunity to pathogenic threats. With a better understanding of immune status and consultation of a physician, patients will be equipped with information to make personalized proactive and protective decisions rather than a one-size-fits-all and reactionary approach that was evident in the global management of Covid-19. DocWire News spoke with with Tomasz George, Chief Scientific Officer at Virax Labs, to learn more about this innovaive company and its platform.